Fibrate and statin combination

This page covers all Fibrate and statin combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PPARα (ABT-335) and HMG-CoA reductase (rosuvastatin).

Targets

PPARα (ABT-335) and HMG-CoA reductase (rosuvastatin)

Phase 3 pipeline (1)

• ABT-335 and rosuvastatin calcium · AstraZeneca · Cardiovascular
  ABT-335 (fenofibrate) reduces triglycerides and raises HDL cholesterol by activating peroxisome proliferator-activated receptor alpha (PPARα), while rosuvastatin calcium lowers LDL cholesterol by inhibiting HMG-CoA reductase.

Patent intelligence

• fibrate and statin combination patent landscape — aggregated cliff calendar, attackable patents, originator estates